Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489823 | 0.81 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL4994919 | 0.80 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL7122083 | 0.79 | HSD17B10 (0.54) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL7122088 | 0.79 | HSD17B10 (0.54) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL7129588 | 0.79 | HSD17B10 (0.54) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL13871981 | 0.79 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL5873417 | 0.78 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL25395953 | 0.78 | HSD17B10 (0.53) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL1584759 | 0.78 | HSD17B10 (0.53) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL903492 | 0.78 | HSD17B10 (0.53) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758525-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| EP-2951184-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014120786-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HSD17B10 2431/4885SMN1; SMN2 913/4885NPC1 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.